Antimoniate of N-methylglucamine — Competitive Intelligence Brief

Antimoniate of N-methylglucamine (Antimoniate of N-methylglucamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiparasitic agent. Area: Infectious Disease.

marketed Antiparasitic agent Leishmania glycolytic enzymes and mitochondrial function Infectious Disease Small molecule

Target snapshot

Antimoniate of N-methylglucamine (Antimoniate of N-methylglucamine) — University of Brasilia. Antimoniate of N-methylglucamine is a pentavalent antimony compound that kills Leishmania parasites by disrupting their metabolism and energy production.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Antimoniate of N-methylglucamine TARGET	Antimoniate of N-methylglucamine	University of Brasilia	marketed	Antiparasitic agent	Leishmania glycolytic enzymes and mitochondrial function
''albendazole'' and ''ivermectin''	''albendazole'' and ''ivermectin''	Centre d'Appui à la lutte contre la Maladie	marketed	Antihelmintic/Antiparasitic agents	β-tubulin (albendazole); glutamate-gated chloride channels (ivermectin)
Ivermectin 1% cream (IVM)	Ivermectin 1% cream (IVM)	Galderma R&D	marketed	Antiparasitic agent	Glutamate-gated chloride channels (invertebrate-specific)
Atovaquone Oral Suspension	Atovaquone Oral Suspension	University of Oxford	marketed	Antiparasitic agent	Cytochrome bc1 complex (Complex III)
Pyrimethamine (PYR)	Pyrimethamine (PYR)	Erasmus Medical Center	marketed	Antifolate antimalarial and antiparasitic agent	Dihydrofolate reductase (DHFR)
Ivermectin 1% cream	Ivermectin 1% cream	Insel Gruppe AG, University Hospital Bern	marketed	Antiparasitic agent	Glutamate-gated chloride channels
Ivermectin (reference)	Ivermectin (reference)	Padagis LLC	phase 3	Antiparasitic agent	Glutamate-gated chloride channels (GluCl)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiparasitic agent class)

1. Actavis Inc. · 2 drugs in this class
2. Galderma R&D · 1 drug in this class
3. Insel Gruppe AG, University Hospital Bern · 1 drug in this class
4. Padagis LLC · 1 drug in this class
5. U.S. Army Medical Research and Development Command · 1 drug in this class
6. University of Brasilia · 1 drug in this class
7. University of Oxford · 1 drug in this class